Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand

Journal of Infectious Diseases

Volumn 196, Issue 11, 2007, Pages 1629-1636

  Jourdain, Gonzague ^a,e,i   Mary, Jean Yves ^b,c   Le Coeur, Sophie ^d,e   Ngo Giang Huong, Nicole ^a,e   Yuthavisuthi, Praparb ^g   Limtraku, Aram ^g   Traisathit, Patrinee ^h   McIntosh, Kenneth ^f   Lallemant, Marc ^a,e  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

^h CHIANG MAI UNIVERSITY   (Thailand)

ⁱ NONE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABOR INDUCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THAILAND; TOCOLYSIS; TREATMENT DURATION; VIRUS LOAD; VIRUS TRANSMISSION; ADULT; ANALYSIS OF VARIANCE; BIRTH; COMPARATIVE STUDY; DISEASE TRANSMISSION; FETUS DISEASE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; NEWBORN; PREGNANCY COMPLICATION; RISK; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; FETAL DISEASES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INFANT, NEWBORN; LOGISTIC MODELS; MALE; ODDS RATIO; PARTURITION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT; RISK FACTORS; THAILAND; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 38449115032     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522009     Document Type: Article

References (34)

1. US Department of Health and Human Services. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, October 12, 2006. Available at: http://www.hivatis.org. Accessed 19 December 2006.
2. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. Recommendations for a Public Health Approach. Geneva: World Health Organization, 2006.
3. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246-7.
4. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998; 352:597-600.
5. Kourtis AP, Bulterys M, Nesheim SR, Lee FK. Understanding the timing of HIV transmission from mother to infant. JAMA 2001; 285:709-12.
6. Blanche S, Rouzioux C, Moscato ML, et al.Aprospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med 1989; 320:1643-8.
7. Thomas PA, Weedon J, Krasinski K, et al. Maternal predictors of perinatal human immunodeficiency virus transmission. The New York City Perinatal HIV Transmission Collaborative Study Group. Pediatr Infect Dis J 1994; 13:489-95.
8. HIV-infected pregnant women and vertical transmission in Europe since 1986: European collaborative study. AIDS 2001; 15:761-70.
9. Borkowsky W, Krasinski K, Cao Y, et al. Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes. J Pediatr 1994; 125:345-51.
10. Fang G, Burger H, Grimson R, et al. Maternal plasma human immunodeficiency virus type 1RNAlevel: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995; 92:12100-4.
11. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-9.
12. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996; 275:599-605.
13. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996; 175:661-7.
14. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study.NEngl J Med 1996; 334:1617-23.
15. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet 1999; 353:1035-9.
16. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med 1999; 340:977-87.
17. Kuhn L, Abrams EJ, Matheson PB, et al. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1997; 11:429-35.
18. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. J Infect Dis 1999; 179:52-8.
19. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 1999; 13:407-14.
20. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005; 38:87-95.
21. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000; 343:982-91.
22. Jourdain G, Comeau AM, Gerstel-Thompson J, et al. Early detection of HIV infection in infants in Thailand using dried blood spots (DBS) and Roche AMPLICOR HIV-1 assay using 1.5 primers [abstract 770]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco, California). Available at: http:// www.retroconference.org/2000/ Abstracts/770.htm. Accessed 14 October 2007.
23. Hosmer DW, Lemeshow S. Model-building strategies and methods for logistic regression. In: Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, 1989:82-133.
24. Prasitwattanaseree S, Lallemant M, Costagliola D, Jourdain G, Mary JY. Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants. Antivir Ther 2004; 9:179-85.
25. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353:773-80.
26. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
27. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-35.
28. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-86.
29. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial. The Mashi Study. JAMA 2006; 296:794-805.
30. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999; 179:567-75.
31. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-28.
32. Vyankandondera J, Luchters S, Hassink E, et al. SIMBA, stopping infection from mother-to-child via breastfeeding in Africa. Uganda AIDS Commission, National AIDS Documentation and Information Centre. Available at: http://www.aidsuganda.org/pdf/PMTCT_SIMBA_Study.pdf. Accessed 14 April 2005.
33. Antiretroviral drugs and the prevention of mother to child transmission of HIV infection in resource-limited settings: recommendation for a public health approach (2005 revision). Geneva: World Health Organization, 2005:4.
34. International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15:357-68.